Stockreport

Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference [Yahoo! Finance]

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF MYQORZO 's label and create a “halo effect” for the oHCM launch; phase 2 dosing showed ~85% of patients reached the highest doses with low interruption rates (~3–5%). [Read more]